SG10201603411WA - Polypeptide constructs and uses thereof - Google Patents
Polypeptide constructs and uses thereofInfo
- Publication number
- SG10201603411WA SG10201603411WA SG10201603411WA SG10201603411WA SG10201603411WA SG 10201603411W A SG10201603411W A SG 10201603411WA SG 10201603411W A SG10201603411W A SG 10201603411WA SG 10201603411W A SG10201603411W A SG 10201603411WA SG 10201603411W A SG10201603411W A SG 10201603411WA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptide constructs
- constructs
- polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011904502A AU2011904502A0 (en) | 2011-10-28 | Polypeptide constructs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201603411WA true SG10201603411WA (en) | 2016-07-28 |
Family
ID=48168677
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201401518TA SG11201401518TA (en) | 2011-10-28 | 2012-10-29 | Polypeptide constructs and uses thereof |
SG10201603411WA SG10201603411WA (en) | 2011-10-28 | 2012-10-29 | Polypeptide constructs and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201401518TA SG11201401518TA (en) | 2011-10-28 | 2012-10-29 | Polypeptide constructs and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (3) | US9611322B2 (en) |
EP (1) | EP3559049A4 (en) |
JP (3) | JP6184965B2 (en) |
KR (2) | KR102037541B1 (en) |
CN (2) | CN109022465B (en) |
AU (2) | AU2012327877B2 (en) |
BR (1) | BR112014009925B1 (en) |
CA (1) | CA2851892C (en) |
EA (2) | EA201700111A1 (en) |
IL (2) | IL232247B (en) |
MX (1) | MX360741B (en) |
NZ (1) | NZ756727A (en) |
SG (2) | SG11201401518TA (en) |
WO (1) | WO2013059885A2 (en) |
ZA (1) | ZA201402819B (en) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003295471B2 (en) * | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
CN102268089A (en) | 2011-07-05 | 2011-12-07 | 上海交通大学 | AGR2 (Anterior Gradient-2) blocking antibody and application thereof |
EP3559049A4 (en) * | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
US9492562B2 (en) | 2012-01-20 | 2016-11-15 | Vib Vzw | Targeted human-interferon fusion proteins |
JP6195855B2 (en) | 2012-03-03 | 2017-09-13 | イミュンジーン,インコーポレーテッド | Engineered antibody-interferon mutant fusion molecules |
AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
EP2992013B1 (en) * | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
EP3022305B1 (en) | 2013-07-18 | 2017-11-01 | Vib Vzw | Fusokines involving cytokines with strongly reduced receptor binding affinities |
MX2016000721A (en) | 2013-07-19 | 2016-09-07 | Vib Vzw | Targeting of cytokine antagonists. |
BR112016001114B1 (en) | 2013-07-19 | 2023-02-14 | Vib Vzw | COMPOSITION COMPRISING A FUSION PROTEIN AND USE OF SUCH COMPOSITION |
US9932409B2 (en) | 2013-07-19 | 2018-04-03 | Vib Vzw | Targeted modified IL-1 family members |
TN2016000142A1 (en) * | 2013-10-31 | 2017-10-06 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers. |
MX2016010128A (en) * | 2014-02-07 | 2017-02-02 | Univ Mcmaster | Trifunctional t cell-antigen coupler and methods and uses thereof. |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
EP3954713A3 (en) | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
WO2016020791A1 (en) * | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
SG11201701867SA (en) | 2014-09-09 | 2017-04-27 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
AU2015337858B2 (en) * | 2014-10-29 | 2020-09-24 | Teva Pharmaceuticals Australia Pty Ltd. | Interferon alpha2b variants |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
BR112017011166A2 (en) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | heterodimeric antibodies that bind to cd3 and cd38 |
WO2016089960A1 (en) | 2014-12-04 | 2016-06-09 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
IL300548A (en) | 2015-05-20 | 2023-04-01 | Janssen Biotech Inc | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies |
US20180312561A1 (en) * | 2015-06-12 | 2018-11-01 | Immungene, Inc. | Focused interferon immunotherapy for treatment of cancer |
EA036789B1 (en) | 2015-06-22 | 2020-12-22 | Янссен Байотек, Инк. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
RU2611685C2 (en) * | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Humanized monoclonal antibody specific to syndecan-1 |
CN105254717B (en) * | 2015-08-18 | 2018-08-24 | 中山大学 | The polypeptide combined with CD34 molecular specificities and its application |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
TWI800341B (en) | 2015-11-03 | 2023-04-21 | 美商健生生物科技公司 | Subcutaneous formulations of anti-cd38 antibodies and their uses |
EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
JP7166923B2 (en) | 2016-02-05 | 2022-11-08 | オリオニス バイオサイエンシズ ビーブイ | Targeted therapeutic agents and their uses |
JP2019507762A (en) | 2016-03-07 | 2019-03-22 | ブイアイビー ブイゼットダブリュー | CD20 binding single domain antibody |
CN106065033A (en) * | 2016-03-17 | 2016-11-02 | 中国药科大学 | The preparation of a kind of cytokine fusion antibody and application thereof |
US11499168B2 (en) * | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
CN109563141A (en) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | To the therapeutic targeting of cellular structures |
MX2018015592A (en) | 2016-06-14 | 2019-04-24 | Xencor Inc | Bispecific checkpoint inhibitor antibodies. |
EA037848B1 (en) | 2016-07-14 | 2021-05-27 | Общество С Ограниченной Ответственностью "Биохимический Агент" | Fusion protein, polynucleotide, genetic construct, producer, preparation for regeneration of cartilage (variants) |
WO2018014068A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Attenuated type i ifn cd47 combination therapy |
WO2018014067A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
ES2917000T3 (en) | 2016-10-24 | 2022-07-06 | Orionis Biosciences BV | Target mutant interferon-gamma and uses thereof |
TW201829463A (en) * | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Anti-hla-g antibodies and use thereof |
CN106854248A (en) * | 2016-12-09 | 2017-06-16 | 中国药科大学 | A kind of preparation and its application of cell factor mutant fusion antibody |
US11267883B2 (en) * | 2016-12-21 | 2022-03-08 | Cephalon, Inc. | Antibodies that specifically bind to human IL-15 and uses thereof |
WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
WO2018141964A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
EP3580230A1 (en) | 2017-02-07 | 2019-12-18 | VIB vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
EP3618870A4 (en) * | 2017-05-01 | 2021-04-21 | The Trustees of The University of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
US20200362058A1 (en) * | 2017-05-24 | 2020-11-19 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
EP3648786A4 (en) * | 2017-07-03 | 2021-12-15 | Torque Therapeutics, Inc. | Fusion molecules targeting immune regulatory cells and uses thereof |
WO2019023156A1 (en) * | 2017-07-24 | 2019-01-31 | Rutgers, The State University Of New Jersey | Phosphatidylserine targeting fusion molecules and methods for their use |
CR20200099A (en) * | 2017-08-03 | 2020-07-24 | Amgen Inc | Interleukin-21 muteins and methods of treatment |
US11498966B2 (en) | 2017-08-09 | 2022-11-15 | Orionis Biosciences Inc. | PD-1 and PD-L1 binding agents |
JP7347899B2 (en) * | 2017-08-09 | 2023-09-20 | オリオンズ バイオサイエンス インコーポレイテッド | CD8 binding substance |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
KR20200079293A (en) | 2017-10-31 | 2020-07-02 | 얀센 바이오테크 인코포레이티드 | How to treat high-risk multiple myeloma |
CR20200330A (en) | 2018-01-12 | 2020-12-23 | Amgen Inc | Anti-pd-1 antibodies and methods of treatment |
WO2019148089A1 (en) * | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
MX2020008208A (en) | 2018-02-05 | 2020-11-09 | Orionis Biosciences Inc | Fibroblast binding agents and use thereof. |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
US20220110872A1 (en) | 2018-12-14 | 2022-04-14 | Morphosys Ag | Antibody formulations |
CA3133831A1 (en) * | 2019-03-28 | 2020-10-01 | Nikolai Kley | Clec9a-based chimeric protein complexes |
WO2020198654A1 (en) * | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
US11655302B2 (en) * | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
WO2021239020A1 (en) * | 2020-05-26 | 2021-12-02 | 上海邦耀生物科技有限公司 | Immunotherapy method for combining chimeric antigen receptor and type i interferon and application thereof |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
WO2022072495A2 (en) * | 2020-10-01 | 2022-04-07 | Academia Sinica | Potent neutralizing antibodies for prevention and treatment of covid-19 |
EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
CN117616050A (en) | 2021-06-09 | 2024-02-27 | 先天制药公司 | Multispecific proteins that bind to NKP46, cytokine receptor, tumor antigen and CD16A |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2023052846A2 (en) * | 2021-09-30 | 2023-04-06 | Ildong Pharmaceutical Co., Ltd. | Immunocytokine containing il-21r mutein |
WO2023178253A2 (en) * | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
CN115057946B (en) * | 2022-06-30 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | Application of interferon in preparation of medicines for resisting broad-spectrum influenza virus and coronavirus |
WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
CN117430716A (en) * | 2023-10-16 | 2024-01-23 | 珠海臻谱基因科技有限公司 | Recombinant interferon drug targeting conserved HIV gp41 subunit near-membrane-end outer region and application thereof |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
KR0184860B1 (en) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | Single domain ligands receptors comprising said ligands methods for their production and use of said ligands |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5976531A (en) | 1990-04-19 | 1999-11-02 | The Dow Chemical Company | Composite antibodies of human subgroup IV light chain capable of binding to tag-72 |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
JP3854306B2 (en) | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Humanized and chimeric monoclonal antibodies |
ES2134212T3 (en) | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | HUMAN ANTIBODY RECONSTITUTED AGAINST THE RECEIVER OF INTERLEUKIN 6 HUMAN. |
US5545533A (en) | 1991-05-25 | 1996-08-13 | Boehringer Mannheim Gmbh | Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US6042828A (en) | 1992-09-07 | 2000-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5441734A (en) * | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
PT699237E (en) | 1994-03-17 | 2003-07-31 | Merck Patent Gmbh | ANTI-EGFR CHAIN FVS AND ANTI-EGFR ANTIBODIES |
ES2167391T3 (en) | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | IMMUNOCONJUGADOS II. |
US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
AU709988B2 (en) | 1995-06-07 | 1999-09-09 | Innogenetics N.V. | Immunotoxins specific for CD80 and CD86 expressing cells |
US5977322A (en) | 1995-06-14 | 1999-11-02 | The Regents Of The University Of California | High affinity human antibodies to tumor antigens |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
CA2250579A1 (en) | 1996-05-04 | 1997-11-13 | Zeneca Limited | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
NZ502375A (en) | 1997-07-14 | 2001-11-30 | Bolder Biotechnology Inc | The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
ES2265693T3 (en) | 1998-10-16 | 2007-02-16 | Biogen Idec Ma Inc. | FUSION PROTEINS WITH INTERFERON-BETA AND USES. |
PT1137789E (en) | 1998-12-09 | 2010-10-21 | Phyton Holdings Llc | A method for manufacturing glycoproteins having human-type glycosylation |
US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
EP1161266A4 (en) | 1999-03-12 | 2007-09-19 | Univ Georgetown | Matriptase, a serine protease and its applications |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
ES2269366T3 (en) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | IMPROVEMENT OF AVERAGE LIFE IN CIRCULATION OF FUSION PROTEINS BASED ON ANTIBODIES. |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
US7521047B2 (en) | 2000-05-12 | 2009-04-21 | Gpc Biotech Ag | Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
JP3597140B2 (en) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof |
AU2001265418B2 (en) | 2000-06-22 | 2006-03-30 | Biogen Idec Inc. | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
KR100787073B1 (en) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | Methods for producing modified glycoproteins |
EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
US7323552B2 (en) | 2000-07-31 | 2008-01-29 | The General Hospital Corporation | Variant integrin polypeptides and uses thereof |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
AR032028A1 (en) | 2001-01-05 | 2003-10-22 | Pfizer | ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR |
FR2823764B1 (en) | 2001-04-24 | 2003-12-12 | Genodyssee | NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFN ALPHA-17 GENE |
US20020193569A1 (en) | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
EP1409544B1 (en) | 2001-07-03 | 2009-06-17 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
AR035119A1 (en) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | ANTI-HTNFSF13B HUMAN ANTI-BODIES |
KR20050036852A (en) | 2001-10-15 | 2005-04-20 | 기린 비루 가부시키가이샤 | Anti-hla-dr-antibody |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
BR0306808A (en) | 2002-01-09 | 2005-08-30 | Medarex Inc | Human Monoclonal Antibodies against cd30 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
EP2865688A1 (en) | 2002-03-01 | 2015-04-29 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
JP2006502110A (en) | 2002-07-03 | 2006-01-19 | イミュノジェン・インコーポレーテッド | Antibodies against non-released Muc1 and Muc16 and uses thereof |
WO2004022747A1 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
MXPA05004712A (en) | 2002-11-07 | 2005-11-23 | Immunogen Inc | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same. |
PL376673A1 (en) | 2003-02-18 | 2006-01-09 | Merck Patent Gmbh | Fusion proteins of interferon alpha muteins with improved properties |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
EP1694706B1 (en) | 2003-11-01 | 2012-04-04 | Merck Patent GmbH | Modified anti-cd52 antibody |
JP4810431B2 (en) | 2003-11-04 | 2011-11-09 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Method for treating cancer associated with B cells |
EP1711527A4 (en) | 2003-12-15 | 2008-09-03 | Dendreon Corp | Hla-dr-specific antibodies, compositions and methods |
CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
ES2541436T3 (en) | 2004-02-06 | 2015-07-20 | Morphosys Ag | Human anti-CD38 antibodies and uses for them |
US8034352B2 (en) | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
PL2287195T3 (en) | 2004-07-01 | 2019-10-31 | Novo Nordisk As | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
WO2006020580A2 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
AU2005295595C1 (en) | 2004-10-15 | 2012-06-21 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
EP1842857B1 (en) * | 2004-11-12 | 2011-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Mutant interferon proteins and use thereof |
SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
EP2799451A1 (en) | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
AU2006250068A1 (en) | 2005-05-26 | 2006-11-30 | Schering Corporation | Interferon-IGG fusion |
US7736647B2 (en) | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
ES2435846T3 (en) | 2005-06-29 | 2013-12-23 | Yeda Research And Development Co. Ltd. | Interferon alpha 2 (IFN alpha 2) mutants recombinant |
EP2388277A3 (en) | 2005-07-18 | 2013-03-20 | Amgen, Inc | Human anti-B7RP1 neutralizing antibodies |
CA2622016A1 (en) | 2005-09-09 | 2007-03-15 | Imperial Innovations Limited | Interferon lambda therapy for treatment of respiratory diseases |
EP1934261B1 (en) | 2005-09-26 | 2014-10-29 | Medarex, L.L.C. | Human monoclonal antibodies to cd70 |
US20070190068A1 (en) * | 2005-10-10 | 2007-08-16 | Richard Hart | uPAR-binding molecule-drug conjugates and uses thereof |
KR101472250B1 (en) | 2005-10-12 | 2014-12-11 | 모르포시스 아게 | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
CA2627890A1 (en) | 2005-10-31 | 2007-05-10 | The Government Of The United States As Represented By The Secretary Of H Ealth And Human Services, National Institutes Of Health | Antibodies and immunotoxins that target human glycoprotein nmb |
GB0525214D0 (en) | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
CN101045156B (en) * | 2006-03-29 | 2012-05-02 | 刘宏利 | Special target medicine and its use |
TWI395754B (en) | 2006-04-24 | 2013-05-11 | Amgen Inc | Humanized c-kit antibody |
EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
FR2905375A1 (en) | 2006-08-29 | 2008-03-07 | Biomethodes Sa | Thermostable variants of human interferon alpha useful for preparing antiviral, antiproliferative or immunomodulatory medicaments have one or more selected amino acid substitutions |
WO2008036688A2 (en) | 2006-09-18 | 2008-03-27 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
US9040050B2 (en) | 2006-09-26 | 2015-05-26 | Genmab A/S | Combination treatment of CD38-expressing tumors |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
RU2549701C2 (en) | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Anti-icos antibodies and their application in treatment of oncological, transplantation-associated and autoimmune diseases |
CA2683568A1 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
EP2152751A1 (en) | 2007-05-31 | 2010-02-17 | Genmab A/S | Fusion or linked proteins with extended half life |
US8248984B2 (en) | 2007-06-20 | 2012-08-21 | I Squared Llc | System and method for interfacing devices |
AU2008282729B2 (en) * | 2007-08-01 | 2015-07-16 | Scott & White Healthcare | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
BRPI0817108B8 (en) | 2007-09-21 | 2021-05-25 | Univ California | composition comprising a fusion protein, kit comprising said composition and use thereof. |
WO2009073975A1 (en) | 2007-12-10 | 2009-06-18 | National Research Council Of Canada | Production of recombinant interferon proteins |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
EP2801584B1 (en) | 2007-12-26 | 2019-07-10 | Biotest AG | Agents targeting CD138 and uses thereof |
JP2011508738A (en) | 2007-12-26 | 2011-03-17 | バイオテスト・アクチエンゲゼルシヤフト | Method and agent for improving targeting of CD138 expressing tumor cells |
US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
EP2313435A4 (en) | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
EA024695B1 (en) | 2009-03-16 | 2016-10-31 | Сефалон Острэйлиа Пти Лтд. | Humanised antibodies with anti-tumour activity |
EP2429582A4 (en) | 2009-05-13 | 2013-01-23 | Genzyme Corp | Anti-human cd52 immunoglobulins |
US8206715B2 (en) | 2010-05-04 | 2012-06-26 | Five Prime Therapeutics, Inc. | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
DK2580243T3 (en) | 2010-06-09 | 2020-01-13 | Genmab As | ANTIBODIES AGAINST HUMAN CD38 |
US8909257B2 (en) | 2010-06-19 | 2014-12-09 | Qualcomm Incorporated | Positioning protocol conveyance |
HUE031956T2 (en) | 2010-09-27 | 2017-08-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
UA112062C2 (en) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | CD33-Binding Agent |
JP6147670B2 (en) | 2010-12-22 | 2017-06-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Modified antibodies with improved half-life |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
EP3559049A4 (en) * | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
US9492562B2 (en) | 2012-01-20 | 2016-11-15 | Vib Vzw | Targeted human-interferon fusion proteins |
JP6195855B2 (en) | 2012-03-03 | 2017-09-13 | イミュンジーン,インコーポレーテッド | Engineered antibody-interferon mutant fusion molecules |
US9783589B2 (en) | 2012-08-13 | 2017-10-10 | Immungene Inc | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
KR20150111958A (en) | 2013-01-25 | 2015-10-06 | 바이엘 머티리얼사이언스 아게 | Security element having volume hologram and printed feature |
EP2992013B1 (en) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
AU2015337858B2 (en) | 2014-10-29 | 2020-09-24 | Teva Pharmaceuticals Australia Pty Ltd. | Interferon alpha2b variants |
-
2012
- 2012-10-29 EP EP12843185.5A patent/EP3559049A4/en active Pending
- 2012-10-29 CN CN201810868213.4A patent/CN109022465B/en active Active
- 2012-10-29 BR BR112014009925-1A patent/BR112014009925B1/en active IP Right Grant
- 2012-10-29 EA EA201700111A patent/EA201700111A1/en unknown
- 2012-10-29 EA EA201400488A patent/EA034989B1/en not_active IP Right Cessation
- 2012-10-29 KR KR1020147014249A patent/KR102037541B1/en active IP Right Grant
- 2012-10-29 CA CA2851892A patent/CA2851892C/en active Active
- 2012-10-29 KR KR1020197031072A patent/KR102096224B1/en active IP Right Grant
- 2012-10-29 MX MX2014005108A patent/MX360741B/en active IP Right Grant
- 2012-10-29 CN CN201280064672.8A patent/CN104203982B/en active Active
- 2012-10-29 NZ NZ756727A patent/NZ756727A/en unknown
- 2012-10-29 WO PCT/AU2012/001323 patent/WO2013059885A2/en active Application Filing
- 2012-10-29 JP JP2014537430A patent/JP6184965B2/en active Active
- 2012-10-29 SG SG11201401518TA patent/SG11201401518TA/en unknown
- 2012-10-29 SG SG10201603411WA patent/SG10201603411WA/en unknown
- 2012-10-29 AU AU2012327877A patent/AU2012327877B2/en active Active
-
2014
- 2014-04-16 ZA ZA2014/02819A patent/ZA201402819B/en unknown
- 2014-04-24 IL IL232247A patent/IL232247B/en active IP Right Grant
- 2014-04-28 US US14/262,841 patent/US9611322B2/en active Active
-
2016
- 2016-06-28 US US15/194,926 patent/US20160367695A1/en not_active Abandoned
-
2017
- 2017-03-02 US US15/447,912 patent/US10981986B2/en active Active
- 2017-07-26 JP JP2017144182A patent/JP2017193580A/en active Pending
-
2018
- 2018-01-11 AU AU2018200221A patent/AU2018200221B2/en active Active
- 2018-06-14 IL IL260045A patent/IL260045B/en active IP Right Grant
-
2019
- 2019-09-02 JP JP2019159406A patent/JP7111669B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL260045B (en) | Polypeptide constructs and uses thereof | |
HUS2100034I1 (en) | Anti-angptl3 antibodies and uses thereof | |
IL288203A (en) | Meditopes and meditope-binding antibodies and uses thereof | |
HK1244490A1 (en) | Anti-phf-tau antibodies and their uses | |
IL230918A0 (en) | Modified proteins and peptides | |
IL232399A0 (en) | Anti-fgfr2 antibodies and uses thereof | |
EP2756094A4 (en) | Anti-b7-h4 antibodies and their uses | |
IL229844B (en) | Anti-psgl-1-antibodies and uses thereof | |
HK1199842A1 (en) | Anti-siglec-15 antibodies and uses thereof -15 | |
EP2738255A4 (en) | Erap1-derived peptide and use thereof | |
EP2793921A4 (en) | Saposin-a derived peptides and uses thereof | |
SG11201402139UA (en) | High mast2-affinity polypeptides and uses thereof | |
EP2762149A4 (en) | Erythropoietin-derived peptide and use therefor | |
EP2693879A4 (en) | Migrastatins and uses thereof | |
EP2771689A4 (en) | Usp2a peptides and antibodies | |
AU2011904502A0 (en) | Polypeptide constructs and uses thereof | |
GB201121226D0 (en) | Modified proteins and peptides | |
GB201121233D0 (en) | Modified proteins and peptides | |
GB201121236D0 (en) | Proteins and peptides |